Senseonics Holdings, Inc. is a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. Its primary product line, the Eversense brand, includes the Eversense E3 and Eversense 365 systems, which utilize an under-the-skin sensor, a removable and rechargeable smart transmitter, and a mobile application to measure glucose levels for periods of up to six or twelve months. The company serves patients and healthcare providers in the United States and select European markets, including the European Economic Area. In January 2026, the company assumed full commercial responsibility for Eversense 365 in the United States, following a transfer of commercial operations from its former partner, Ascensia Diabetes Care Holdings AG. Ascensia retains non-exclusive marketing rights in Italy, Germany, Spain, and Sweden. The company is also developing future product variations, including the Gemini system, which combines continuous and flash glucose monitoring, and the Freedom system, which integrates Bluetooth technology into the sensor to eliminate the on-body component.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Devices Homepage senseonics.com
Sector Healthcare IR page senseonics.com/investor-relations
Tags
continuous glucose monitoring, implantable sensors, diabetes management, medical technology, smart transmitters, mobile health applications, Eversense, Eversense E3, Eversense 365, Eversense XL, Gemini, Freedom, twiist, Ascensia Diabetes Care Holdings AG
Press page —

Metrics

Valuation  
Market cap $ 565.283M
Market cap (USD) $ 565.283M
P/E -3.41
PEG —
P/BV 7.28
P/S 9.42
P/OCF -5.00
P/FCF -4.96
Dividend yield —
Turnover / mcap —
Returns  
ROE -113.2%
ROI -71.5%
ROIC -53.0%
Profit margin -196.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock —
Diluting (TTM) Yes
Debt/Equity 69.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 33
Quality score -50.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 35.257M 22.472M 22.39M 656K 1.394M 1.368M 4.924M 18.913M 6.373M 332K — —
Net profit -69.113M -78.616M -60.392M 142.119M -302.474M -175.168M -115.549M -93.971M -59.101M -43.93M -29.877M -18.885M
Free cash flow -60.245M -62.704M -70.513M -66.624M -56.288M -67.603M -137.092M -91.76M -56.084M -38.495M -25.667M -19.299M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 5.52 0.52 0.57 1.03 2.67 0.87 0.92 2.59 2.66 2.67 — —
Price performance 12m 9.55 -0.08 -0.45 -0.61 2.06 -0.05 -0.65 -0.03 -0 — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — — — — — 6.29M 12.1M
↳ YoY growth +92.8%
Lease liabilities (USD) — — 2.32M 2.97M 2.28M 1.48M 3.41M 6.58M 6.21M 5.79M
Cash and deposits (USD) 13M 16.2M 137M 95.9M 18M 33.5M 35.8M 75.7M 74.6M 40.2M
Intangible assets (USD) — — — — — — — — — 600,000
Right-of-use assets (USD) — — 2.24M 2.82M 2.13M 821,000 3.03M 5.18M 4.84M 4.46M
Cash flow detail
Operating cash flow (USD) -38M -55.7M -90.8M -136M -67.4M -56.1M -66.3M -70.2M -60.5M -59.1M
Purchases of property, plant and equipment (USD) -479,000 -345,000 -989,000 -1.05M -181,000 -210,000 -312,000 -350,000 -2.24M -1.12M
Change in receivables (cash effect) (USD) 250,000 -3.13M -3.72M -3.28M 7.39M 1.01M -478,000 -2.19M -2.7M -6.77M
Change in inventories (cash effect) (USD) -477,000 -2.74M -7.44M -10.7M 15.8M -1.04M -989,000 -1.64M 696,000 -2.98M
Change in payables (cash effect) (USD) 1.82M 4.64M -3.4M -122,000 -2.52M -559,000 -785,000 2.3M -1.83M 1.22M
Interest paid (cash effect) (USD) -893,000 -1.83M -3.14M -5.23M -4.73M -7.82M -6.57M -3.68M -4.51M -4.05M
Income taxes paid (cash effect) (USD) — — — — — — — — — 0.00
Share-based compensation (USD) 2.42M 3.99M 6.41M 8.05M 7.31M 9.03M 8.62M 8.67M 9.23M 10.2M
Operating cash flow before change in receivables (USD) -38.3M -52.6M -87.1M -133M -74.8M -57.1M -65.8M -68M -57.8M -52.4M
Free cash flow (OCF - PPE - intangibles) (USD) -38.5M -56.1M -91.8M -137M -67.6M -56.3M -66.6M -70.5M -62.7M -60.2M
Income detail
Research and development expense (USD) 26.3M 30.7M 31.9M 38.4M 20.4M 27.2M 39.7M 48.8M 41.1M 31.6M
↳ 5y CAGR +24.4% +2.3% +0.7% +5.3% +8.9% +1.4% +9.1%
Total comprehensive income (USD) -43.9M -59.1M -94M -116M -175M -303M 142M -59.7M -78.6M -69M
Comprehensive income to owners (USD) -43.9M -59.1M -94M -116M -175M -303M 142M -59.7M -78.6M -69M
Provision for credit losses (USD) — — — — — — — — 220,000 931,000
Credit cost ratio (credit losses / average receivables) (%) — — — — — — — — — 10.1%
Reported Feb 23, 2017 Mar 13, 2018 May 9, 2019 Mar 16, 2020 Mar 5, 2021 Mar 1, 2022 Mar 16, 2023 Mar 1, 2024 Mar 2, 2026 May 7, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

● Generated third quarter revenue of $19.6 million, an increase of approximately 140% year-over-year

● Raised full-year 2026 revenue guidance to $68 million to $70 million from $62 million to $66 million, representing year-over-year growth of 93% to 98%

● Achieved gross margin of approximately 62% during Q3, and raising full-year gross margin guidance to more than 60% from 58% to 61%

GERMANTOWN, MD., November 9, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a diabetes company redefining continuous glucose monitoring (CGM) with long-term implantable sensing technology, today announced third quarter 2026 financial results and provided a business update.

Recent Highlights & Accomplishments

● Drove third consecutive quarter of strong execution and performance since bringing U.S. Eversense® commercial operations in-house, delivering expansion of third quarter revenue to $19.6 million and gross margins to approximately 62%

● U.S.

October 26, 2026

Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World’s First CGM System with No On-body Component

First clinical evaluation of investigational, transmitter-free one-year CGM marks an important milestone on Senseonics’ innovation roadmap, with potential launch in 2028

Built on the proven sensing technology behind Eversense 365 and supported by encouraging preclinical data to reduce development risk

GERMANTOWN, Md., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a diabetes company redefining continuous glucose monitoring (CGM) with long-term implantable sensing technology, today announced the initiation of its first-in-human clinical study evaluating Freedom, an investigational next-generation CGM system designed to communicate directly with a mobile device without the need for an external on-body transmitter.

Freedom represents an important step in Senseonics' innovation pipeline and is being developed with a vision to make diabetes technology less visible and burdensome. It is an evolution of the same fundamental sensing technology as the Eversense® 365 system, with the addition of an integrated battery and embedded Bluetooth communication capability. It is designed to have no requirement for an on-body component, while maintaining the benefits people already value with Eversense 365, providing exceptional accuracy over a full year with a single sensor.

"Now being tested in humans for the first time, the Freedom CGM represents our vison to eliminate the requirement for an on-body component, effectively making continuous glucose monitoring invisible. We believe this represents an extremely attractive proposition for millions of people with diabetes and we are proudly leading the race to get there,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. "At Senseonics, we are not interested in incremental innovation. Our mission is to transform lives in the diabetes community and push the boundaries of sensing technology to improve health and wellbeing. Eversense 365 redefined what a CGM could be by becoming the world's first and only one-year system and we are just getting started."

The initiation of this first-in-human clinical study is a key milestone for Senseonics as the Company continues to invest in its innovation pipeline. It is an early feasibility study to evaluate the device design concept with respect to clinical safety and device functionality, including the sensor’s direct Bluetooth communication capabilities. The study’s purpose is to demonstrate safety and generate insights to inform a planned pivotal study that Senseonics expects to initiate in 2027, with the company targeting a potential commercial launch in 2028.

The initiation of the first-in-human study follows encouraging results from preclinical studies completed during the second quarter of 2026, which evaluated multiple Bluetooth® Low Energy (BLE) antenna designs and implantation locations to optimize communication performance and guide configuration selection. Across approximately seven weeks of testing and more than 18,500 communication data points, the preferred design demonstrated 100% communication success within our target distance. As a result, the study identified a preferred antenna configuration and implantation approach for human evaluation.

“Freedom exemplifies our approach to innovation at Senseonics. We are focused on developing game-changing advances that simplify life with diabetes and help make diabetes technology less visible,” Mukul Jain, PhD, Chief Operating Officer of Senseonics, commented. “This R&D approach leverages validated technologies wherever possible to reduce risk and accelerate innovation. Supported by encouraging preclinical communication data, we are excited to begin evaluating Freedom in humans. This program is being driven by what we consistently hear from people living with diabetes and it is what Senseonics was founded to deliver – a one-year CGM sensor with nothing required on-body.”

**About Senseonics
**Senseonics Holdings, Inc. ("Senseonics") is a diabetes company redefining continuous glucose monitoring (CGM) with long-term implantable sensing technology. Driven by a mission to transform lives in the diabetes community, Senseonics is the maker of Eversense® 365, the world's first and only one-year CGM system, and is advancing a differentiated pipeline of innovation.

By commercializing Eversense 365 and pushing the boundaries of sensing technology, Senseonics is empowering better diabetes management, reducing the device burden, expanding patient choice, and shaping the future of diabetes care.

October 22, 2026

Senseonics Holdings, Inc. to Participate in Upcoming Investor Conferences

GERMANTOWN, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the following investor conferences in November:

Stifel 2026 Healthcare Conference – November 10-12, 2026 (New York, NY)
Management will participate in a fireside chat at 3:20 pm ET and host one-on-one meetings with investors on Tuesday, November 10th. Click here to access the live webcast.

20th Annual Canaccord Genuity MedTech, Diagnostics & Digital Health Forum – November 11, 2026 (New York, NY)
Management will present at 10:30 am ET and will host one-on-one meetings with investors on Wednesday, November 11th. Click here to access the live webcast.

Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com .

About Senseonics

Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
[email protected]


Primary Logo

Source: Senseonics Holdings, Inc.

<< Back to 2026 News Releases

Prompts

Senseonics Holdings, Inc. (ticker SENS), listed in United States.

Company History

Date Change Detail
Dec 10, 2015 Renamed ASN TECHNOLOGIES, INC. → SENSEONICS HOLDINGS, INC.

ETFs Holding Senseonics Holdings, Inc.

ETF Weight in ETF Shares Market value As of
DFUS 0.00% 5,050 $ 50.702K Nov 12, 2026
DFAC 0.00% 9,459 $ 94.968K Nov 12, 2026
AVSC 0.00% 1,312 $ 14.301K Nov 16, 2026